Clinical trials: Diabetes Type II
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes
The main objective of this study is to identify the dose of linagliptin in paediatric patients. Other efficacy objectives include the comparison of the lowering effect of linagliptin low dose, high dose and placebo on the fasting…
- Trial name
- NCT01342484
- Testing
- BI1356 low dose, BI1356 high dose
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
The purpose of this study is to evaluate the cardiovascular (CV) safety profile of omarigliptin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01703208
- Testing
- Omarigliptin
- Volunteers
- 4,202 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease
Amlexanox for Type 2 Diabetes and Obesity
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day.
- Conditions
- Diabetes Mellitus Type 2, Non Alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01842282
- Testing
- Amlexanox
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Type2 Diabetes, Cardiovascular Diseases
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes medication, on measures of nervous system function of the heart in patients with type 2 diabetes.
- Trial name
- NCT02973477
- Testing
- Dapagliflozin, Glimepiride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Michigan
Diabetes Mellitus, Type 2
Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose
The purpose of this study is to measure the effect of LY2189265 to increase insulin levels in response to glucose intake.
- Trial name
- NCT01300260
- Testing
- LY2189265, Insulin, Glucose
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOPE (NCT00510952)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Prediabetes
ForgIng New Paths to Prevent DIabeTes (FINDIT)
This study will evaluate the effects of screening for type 2 diabetes mellitus (T2DM) and brief counseling about screening test results on weight and key health behaviors among Veterans with risk factors for T2DM.
- Trial name
- FINDIT (NCT02747108)
- Testing
- Blood Test Group Intervention, Brochure Group Intervention
- Where
- United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus, Hospitalization
Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery…
- Conditions
- Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
- Trial name
- NCT01378117
- Testing
- Sitagliptin, glargine, lispro
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Emory University
Type2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to placebo as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03259789
- Testing
- Bexagliflozin tablets, 20 mg
- Where
- 43 sites in United States, Japan
- Volunteers
- 351 people
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).
- Trial name
- NCT03952143
- Testing
- LY900014, Insulin Lispro, Insulin Glargine
- Where
- 41 sites in Argentina, China and 1 more
- Volunteers
- 628 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
The purpose of this study is to evaluate the efficacy and safety of trelagliptin when administered at a dose of 25 mg once weekly using placebo as a control in patients with type 2 diabetes mellitus complicated by severe renal…
- Trial name
- NCT02512068
- Testing
- Trelagliptin 25 mg
- Where
- 49 sites in Japan
- Volunteers
- 107 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea
This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea)…
- Trial name
- NCT02471404
- Testing
- Dapagliflozin, Saxagliptin, Glimepiride
- Where
- 173 sites in Czechia, Germany and 3 more
- Volunteers
- 939 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Research Design/Plan: After screening, each subject will receive 1 measurements of Endogenous Glucose Production [EGP] with prime-continuous Infusion of 3-3H-glucose.
- Trial name
- NCT03331289
- Testing
- Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Diabetes Mellitus
Evaluation of a Primary Type 2 Diabetes Prevention Programme
A type 2 diabetes prevention programme, named PREDIAS was developed. It consists of 12 lessons delivered as group sessions. Die efficacy of PREDIAS was studied in a randomized controlled study with 12 month follow up.
- Trial name
- PREDIAS (NCT00707447)
- Testing
- PREDIAS, Control
- Where
- Germany
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Forschungsinstitut der Diabetes Akademie Mergentheim
Diabetes Mellitus, Type 2
PMS of Trazenta on the Long-term Use as Add-on Therapy
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as add-on therapy in patients with type 2 diabetes mellitus.
- Trial name
- NCT01904383
- Testing
- Trazenta
- Where
- Japan
- Volunteers
- 4,057 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
Squamous Cell Carcinoma of the Head and Neck
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy
In this Phase II trial of personalized immunotherapy in R/M HNSCC, gene expression of LAG3 and CTLA4 by RNA seq will be determined to select the appropriate agent (Ipilimumab or Relatlimab) to add to Nivolumab in patients with…
- Trial name
- NCT04326257
- Testing
- Nivolumab+Relatlimab, Nivolumab+Ipilimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dan Zandberg
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to compare efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in combination with metformin in subjects with type 2 diabetes…
- Trial name
- NCT02420262
- Testing
- insulin degludec/liraglutide, insulin glargine, insulin aspart
- Where
- 117 sites in United States, Argentina and 10 more
- Volunteers
- 506 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.